Table 2. Camrelizumab treatments.
Variables | Total (n=403) |
---|---|
Treatment line, n (%) | |
First line | 126 (31.3) |
Second line | 164 (40.7) |
Third or later line | 113 (28.0) |
Duration of treatment, weeks, median (range) | 21.9 (12.1–35.3) |
Treatment cycles, median [range] | 6 [1–24] |
Treatment patterns, n (%) | |
Camrelizumab monotherapy | 43 (10.7) |
Camrelizumab plus chemotherapy | 261 (64.8) |
Camrelizumab plus others* | 99 (24.6) |
*, others including anti-angiogenesis therapy or plus chemotherapy, or targeted therapy.